Dublin, May 02, 2025 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global radiopharmaceuticals market is expected to grow from $10.3 billion in 2024 and is projected to reach $21.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 16.4% during the forecast period of 2024 to 2029.
Radiopharmaceuticals are comprised of small amounts of radioisotopes that can be produced by irradiating a particular target inside a nuclear research reactor or particle accelerator, the latter of which uses cyclotrons. Once the radioisotopes are produced, they can be tagged to specific molecules depending on key biological characteristics through a linker that binds the radioisotope and the carrier together to produce radiopharmaceuticals.
Radiopharmaceuticals are used for diagnostic and therapeutic applications. Diagnostic radiopharmaceuticals travel to the targeted area based on the biological molecule's affinity. The radioactive isotope emits gamma rays or positrons, which are detected by molecular imaging devices such as single-photon emission computerized tomography (SPECT) and positron emission tomography (PET) scanners.
Therapeutic radiopharmaceuticals use high-energy cell-killing radioisotopes, such as actinium or lutetium. Therapeutic radiopharmaceuticals use radiation to destroy or weaken malfunctioning cells. The tagged compound delivers therapeutic doses of radiation to targeted body parts to regress or kill malignant cells. Radiopharmaceuticals are used primarily for treating prostate cancer, neuroendocrine tumors (NETs), and thyroid disorders.
Report Scope
This report analyzes the global market for radiopharmaceuticals, in terms of quantitative and qualitative data, to help readers understand the market, to assess business/growth strategies, and to make informed business decisions regarding radiopharmaceuticals. The report estimates market data for 2023 (the base year) and 2024 and forecasts values for 2025 through 2029. The radiopharmaceuticals market segmentation is based on product, application, production method, countries and regions.
Drivers, restraints and opportunities in the radiopharmaceuticals market are also discussed. The report also describes the competitive landscape of the radiopharmaceuticals market and highlights emerging trends. The latest new products, acquisitions, and collaborations related to the radiopharmaceuticals market are also covered.
The report includes:
- 50 data tables and 68 additional tables
- Analyses of trends in the global market for radiopharmaceuticals, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the size, and revenue prospects for, the global market, along with a market share analysis by product type, application, production method, and region/country
- Facts and figures pertaining to the market dynamics, technological progress, regulations, prospects, innovations and the impact of various macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply/value chain and PESTLE analyses
- An analysis of patents, clinical trials, emerging trends and other developments in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Cardinal Health, Lantheus, Curium, GE Healthcare, and Novartis.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 163 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value (USD) in 2024 | $10.3 Billion |
| Forecasted Market Value (USD) by 2029 | $21.9 Billion |
| Compound Annual Growth Rate | 16.4% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Radiopharmaceuticals Overview
- Preparation of Radiopharmaceuticals
- Macroeconomic Factors Analysis
- Porter's Five Forces Analysis
Chapter 3 Market Dynamics
- Market Drivers
- Rising Prevalence of Cancer and Other Chronic Diseases
- Unmet Need in Oncology
- Precision Medicine
- Nuclear Imaging Technologies
- Increasing Investment
- Market Restraints
- Manufacturing and Supply Chain Issues
- Infrastructure and Specialized Imaging Equipment Requirements
- Shortage of Skilled Professionals
- Market Trends
- Theranostics
- Regional Diversification and Supply Chain Resilience
- Opportunities
- Radiopharmaceuticals Contract Manufacturing
- PET Imaging in AD
Chapter 4 Regulatory Landscape
- U.S.
- European Union
- Japan
Chapter 5 Emerging Technologies and Developments
- Emerging Technologies
- Ac-225 and Pb-212
- Nanoparticle-based Theranostic Agents
- Clinical Trials Analysis
- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
- Patent Analysis
- Key Takeaways
Chapter 6 Market Segmentation Analysis
- Radiopharmaceuticals Market, by Product Type
- Diagnostic Radiopharmaceuticals Market, by Imaging Technique Type
- Diagnostic Radiopharmaceuticals Market, by Production Method
- Therapeutic Radiopharmaceuticals Market, by Product Type
- Radiopharmaceuticals Market by Application
- Market Overview
- Oncology
- Cardiology
- Neurology
- Others
- Radiopharmaceuticals Market by Radioisotope Production Method
- Market Overview
- Market Revenue and Forecast
- Radiopharmaceuticals Market Breakdown by Region
Chapter 7 Competitive Intelligence
- Overview
- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
Chapter 8 Sustainability in Radiopharmaceuticals Market: ESG Perspective
- Role of ESG in the Radiopharmaceuticals Industry
- Environment
- Social
- Governance
- ESG Risk Ratings
Company Profiles
- Bayer AG
- Blue Earth Diagnostics
- Boston Scientific Corp.
- BWXT Medical Ltd.
- Cardinal Health
- Curium
- Eckert & Ziegler
- GE HealthCare
- International Isotopes Inc.
- IONETIX Corp.
- Jubilant Pharmova Ltd.
- Lantheus
- NMR
- Novartis AG
- Siemens Healthineers AG
For more information about this report visit https://www.researchandmarkets.com/r/ld6nos
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
